A comparative prospective study of conventional regimen with chronic low-dose administration of follicle-stimulating hormone for anovulation associated with polycystic ovary syndrome.
OBJECTIVE
To compare efficiency of conventional and chronic low-dose regimens for treatment of anovulation associated with polycystic ovary syndrome (PCOS).


METHODS
Fifty participants divided into two equal groups. The first group was treated with urinary human FSH using a conventional stepwise protocol and the second group was treated with a regimen of chronic low-dose and small incremental rises with urinary human FSH or with recombinant human FSH for a maximum of three cycles.


METHODS
Tertiary referral university hospital fertility unit.


METHODS
Fifty infertile women with clomiphene citrate-resistant anovulation associated with PCOS.


METHODS
Pattern of follicular development, amount of FSH required, serum E2 concentrations, cycle fecundity, cumulative conception, and live birth rates. Multiple pregnancy and ovarian hyperstimulation syndrome (OHSS) rates.


RESULTS
Compared with the conventional dose protocol, the chronic low-dose regimen yielded slightly improved pregnancy rates (40% versus 24%) while completely avoiding OHSS and multiple pregnancies, which were prevalent (11% and 33%, respectively) with conventional therapy. Monofollicular development was induced in 74% versus 27% of cycles, and the total number of follicles > 16 mm and E2 concentrations were half those observed on conventional therapy.


CONCLUSIONS
For women with PCOS, a chronic low-dose regimen of FSH eliminated complications of OHSS and multiple pregnancies while maintaining a satisfactory pregnancy rate. This modality, thus, has distinct advantages and could well replace conventional gonadotropin therapy for these patients.
Homburg
R
R
Fertility Unit, Golda Meir Medical Center, Petah Tiqva, Israel.
Levy
T
T
Ben-Rafael
Z
Z
D000328:Adult; D000858:Anovulation / Q000188:drug therapy* / Q000209:etiology*; D002996:Clomiphene / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D004351:Drug Resistance; D005260:Female; D005640:Follicle Stimulating Hormone / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D016471:Ovarian Hyperstimulation Syndrome / Q000139:chemically induced; D010062:Ovulation Induction / Q000379:methods; D011085:Polycystic Ovary Syndrome / Q000150:complications*; D011247:Pregnancy; D011272:Pregnancy, Multiple; D011446:Prospective Studies; D011994:Recombinant Proteins
D011994:Recombinant Proteins; D002996:Clomiphene; D005640:Follicle Stimulating Hormone